Trials / Completed
CompletedNCT00108758
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | activated recombinant human factor VII |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2005-04-19
- Last updated
- 2017-01-12
Locations
37 sites across 12 countries: United States, Argentina, Brazil, Bulgaria, France, Philippines, Poland, Romania, Russia, South Africa, Spain, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00108758. Inclusion in this directory is not an endorsement.